Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...
10x Genomics Inc (TXG) Q4 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...
Despite a challenging macro environment, 10x Genomics Inc (TXG) focuses on product innovation and biopharma expansion to ...
10x Genomics, Inc. (NASDAQ:TXG) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...
10x Genomics sees robust growth across platforms in Q4 2023
CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...
GEN4d
Billion Cells Project Launched by Chan Zuckerberg Initiative to Train New AI Cell Models
Landmark single-cell dataset of one billion cells will be used to train new AI models to advance understanding of cellular ...
Earnings call transcript: 10X Genomics Q4 2024 misses EPS forecast, stock dips
X Genomics Inc . (NASDAQ:TXG) reported its Q4 2024 earnings, revealing a larger-than-expected loss per share and a decline in revenue compared to the previous year. The company posted an EPS of -$0.40 ...